Page 1

☐ ☑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D.C. 20549 FORM 20 - F ( Mark One ) REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report_ For the transition period from to Commission file number 001-36288 Akari Therapeutics , PLC ( Exact name of Registrant as specified in its charter ) The Laws of England and Wales ( Jurisdiction of incorporation or organization ) 75/76 Wimpole Street London W1G 9RT United Kingdom ( Address of principal executive offices ) Clive Richardson Chief Executive Officer 75/76 Wimpole Street London W1G 9RT United Kingdom Telephone +44 20 8004 0270 ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act . Title of each class American Depositary Shares , each Trading Symbol ( s ) AKTX Name of each exchange on which registered The Nasdaq Capital Market representing 100 Ordinary Shares , par value $ 0.0001 per share Ordinary Shares , $ 0.0001 par value per share * * Not for trading , but only in connection with the registration of American Depositary Shares ( ADS ) representing such Ordinary Shares pursuant to the requirements of the Securities and Exchange Commission . Securities registered or to be registered pursuant to Section 12 ( g ) of the Act . None Securities for which there is a reporting obligation pursuant to Section 15 ( d ) of the Act . None